Infinity Pharmaceuticals Inc (INFI)

HEALTH CARE: PHARMACEUTICALS
SIC: PHARMACEUTICAL PREPARATIONS

1100 MASSACHUSETTS AVENUE CAMBRIDGE, MA 02138

Provides products and services designed to make the drug discovery process faster, less expensive and more likely to generate a quality drug candidate. Offers products and services in many functional disciplines of the drug discovery process that can be purchased solo or as integrated solutions.

Data as of 2020-11-22
Market Cap137.402 Million Shares Outstanding64.207 Million Avg 30-day Volume801.647 Thousand
P/E Ratio-3.0 Dividend Yield EPS-0.71
Price/Sales86.308 Price cash flow ratio8.5 Price free cash flow ratio-3.7
Book Value-0.22 Price to Tangible Book-9.73 Alpha-0.02
Short Interest Ratio % Short Interest to Float R-squared0.102728
BETA1.82265 52-week High/Low2.17 / 0.6 Stddev0.239641
View SEC Filings from INFI instead.
Q3 2020 All 13F Filers Prior Change Hedge Funds 1 Prior Change
In top 10: 0 0 0 (0.0%) 0 (0.0%)
Funds Holding: 45 48 -6.25% 13 (0.85%) 13 (0.84%) 0.0%
13F shares: 30.601 Million 27.784 Million 10.14% 25.824 Million 23.169 Million 11.46%
% Ownership 51.9794 47.1952 10.14% 43.865 39.3555 11.46%
New Positions: 3 6 -50.0% 1 1 0.0%
Increased Positions 9 13 -30.77% 3 4 -25.0%
Closed Positions 5 6 -16.67% 1 3 -66.67%
Reduced Positions 11 8 37.5% 3 3 0.0%
Total Calls 36.236 Thousand 4.11 Thousand 781.65%
Total Puts 31 0
PUT/CALL Ratio 0.0 0.0
1 hedge funds and active managers as identified by whalewisdom.com through public filings.

View recent insider trading info

Funds Holding INFI (via 13F filings)

Refresh Download CSV Download Excel (.xlsx) Download TSV
Filter by:
to
to
to
Refresh
*Shares are split adjusted
*Please note that if a filer hasn't submitted a 13F filing for a quarter then the filer's shares will be listed as "Sold All"

Mutual Funds Holding INFI BETA

Active Schedule 13D and 13G filings

Please sign in first

Open Market Buys/Sells Last 60 Days

Open Market Buys (P)

none

Open Market Sells (S)

none

Exercise Derivative Conversion (M)

none

Current/Former Insiders

Insider Name Type Last Reported Shares Held Last Reported Date Filings in past year

SELBY NORMAN C

  • Director
0 2020-06-17 1

EVNIN ANTHONY B

  • Director
165,964 2020-06-17 1

VENUTI MICHAEL C

  • Director
0 2020-06-17 1

BEIER DAVID W

  • Director
0 2020-06-17 1

AGRESTA SAMUEL

  • Director
0 2020-06-17 1

GAYNOR RICHARD

  • Director
0 2020-03-16 2

PERKINS ADELENE Q CHIEF EXECUTIVE OFFICER

  • Officer
809,637 2020-01-10 1

BLOCH LAWRENCE E PRESIDENT

  • Officer
758,308 2020-01-10 1

TASKER SETH A CHIEF BUSINESS OFFICER

  • Officer
113,275 2020-01-10 1

KUTOK JEFFERY CHIEF SCIENTIFIC OFFICER

  • Officer
88,120 2020-01-10 1

BERKOWITZ JEFFREY

  • Director
85,238 2019-06-13 0

KAUFFMAN MICHAEL

  • Director
0 2019-06-13 0

BVF PARTNERS L P/IL

BIOTECHNOLOGY VALUE FUND L P

BIOTECHNOLOGY VALUE FUND II LP

BIOTECHNOLOGY VALUE TRADING FUND OS LP

BVF PARTNERS OS LTD.

BVF INC/IL

LAMPERT MARK N

  • 10% Owner
  • SEE EXPLANATION OF RESPONSESSEE EXPLANATION OF RESPONSES
7,886,129 2018-12-13 0

SMITH IAN F

  • Director
45,845 2018-06-12 0

BASELGA JOSE

  • Director
0 2017-01-06 0

KANGO SUJAY CHIEF COMMERCIAL OFFICER

  • Officer
No longer subject to file 2016-12-12 0

ADAMS JULIAN PRESIDENT OF R&D

  • Officer
No longer subject to file 2016-10-31 0

LANDER ERIC S

  • Director
No longer subject to file 2016-06-17 0

LINDBLOM CHRISTOPHER M PRINCIPAL ACCOUNTING OFFICER

  • Officer
0 2016-05-02 0

BERTRAND WILLIAM C JR GENERAL COUNSEL

  • Officer
No longer subject to file 2015-10-19 0

PALOMBELLA VITO J. CHIEF SCIENTIFIC OFFICER

  • Officer
No longer subject to file 2015-06-15 0

FYFE GWEN A.

  • Director
No longer subject to file 2015-06-15 0

LAM WINSTON K.C. GENERAL COUNSEL

  • Officer
0 2015-04-15 0

ROTH DAVID CHIEF MEDICAL OFFICER

  • Officer
No longer subject to file 2015-01-14 0

SANTABARBARA PEDRO CHIEF MEDICAL OFFICER

  • Officer
No longer subject to file 2014-01-10 0

LYNCH THOMAS J. JR.

  • Director
0 2013-06-11 0

BABLER MARTIN

  • Director
0 2013-06-11 0

ROSEBAY MEDICAL CO L.P.

  • 10% Owner
No longer subject to file 2013-04-16 0

BEACON CO

  • 10% Owner
No longer subject to file 2013-04-16 0

HAMERMESH JOSHUA VP, BUSINESS & CORPORATE DEV

  • Officer
0 2013-01-04 0

TUCKER WINSELOW S. JR. VICE PRESIDENT, MARKETING

  • Officer
0 2013-01-04 0

HOLTZMAN STEVEN H

  • Director
3,945 2012-05-31 0

LEE PATRICK PAK-TIN

  • Director
0 2012-05-16 0

QUIRK GERALD E SEE REMARKS

  • Officer
0 2012-01-06 0

LEVINE ARNOLD J

  • Director
0 2011-05-18 0

TANANBAUM JAMES B

  • Director
0 2011-05-18 0

MOSS FRANKLIN

  • Director
0 2010-05-25 0

TONG JEFFREY K VP, COR. & PRODUCT DEVELOPMENT

  • Officer
0 2010-01-05 0

HIXSON HARRY F JR

  • Director
0 2009-06-17 0

SATO VICKI L

  • Director
0 2008-05-22 0

Insider Transactions Last 60 Days

Reporting Owners Filing Date Trans Date Trans Code Shares Share Price Acquired
Disposed
Shares Owned after D/I 10b5 Perf 1d* Perf 5d* Perf 1m* Max Gain Max Gain Days Max Loss Max Loss Days

AGRESTA SAMUEL - Director

2019-10-16 19:18:42 -0400 2020-10-16 A 60,000 a 60,000 direct

* -

Transaction Code Definitions
Code Definition
A Grant, award or other acquisition pursuant to Rule 16b-3(d)
C Conversion of derivative security
D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)
E Expiration of short derivative position
F Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3
G Bona fide gift
H Expiration (or cancellation) of long derivative position with value received
I Discretionary transaction in accordance with Rule 16b-3(f) resulting in acquisition or disposition of issuer securities
J Other acquisition or disposition
L Small acquisition under Rule 16a-6
M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3
O Exercise of out-of-the-money derivative security
P Open market or private purchase of non-derivative or derivative security
S Open market or private sale of non-derivative or derivative security
U Disposition pursuant to a tender of shares in a change of control transaction
W Acquisition or disposition by will or the laws of descent and distribution
X Exercise of in-the-money or at-the-money derivative security
Z Deposit into or withdrawal from voting trust

Elevate your investments